1256P - Value of detection of peripheral blood circRNA based on digital PCR in the diagnosis of lung adenocarcinoma

Background

Lung cancer is a cancer type with high morbidity and mortality in the word, the clinical prognosis of lung cancer patients is still poor, the main reason is the lack of effective early screening and diagnosis methods. Plasma circRNAs detected by droplet digital PCR may be ideal markers for liquid biopsy. However, droplet digital PCR detection of circRNAs in plasma for (early) diagnosis of lung adenocarcinoma has been rarely reported.

Methods

RNA sequencing analysis was performed in plasma from patients with early lung adenocarcinoma and healthy individuals. Droplet digital PCR was used to verify the differentially expressed genes. We evaluated their diagnostic efficacy and predict their biological functions of target genes.

Results

The copy numbers of circLZIC and circCEP350 in the plasma of lung adenocarcinoma patients were significantly higher than in plasma of healthy people (P＜0.01), they are closely related to tumor size (P＜0.05) and TNM stage (P＜0.05),and the copy numbers in postoperative plasma of the same patient were significantly lower than those in preoperative plasma (P＜0.05).ROC curve analysis showed that circLZIC (AUC=0.782) and circCEP350 (AUC=0.764) alone and in combination (AUC=0.863) had diagnostic value in lung adenocarcinoma, circLZIC (AUC=0.786) and circCEP350 (AUC=0.546) alone and in combination (AUC=0.803) had diagnostic value in early lung adenocarcinoma.Bioinformatics analysis revealed that circLZIC and circCEP350 had more binding sites with multiple microRNAs. Their target genes were enriched in several signaling pathways.

Conclusions

The copy numbers of circLZIC and circCEP350 were higher in plasma of lung adenocarcinoma patients than in plasma of healthy controls, significantly correlated with tumor size and TNM stage, and closely related to the occurrence and development of tumors. These circRNAs may serve as molecular markers for the diagnosis of lung adenocarcinoma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.